
Unlearn.AI uses AI-generated digital twins to make clinical trials faster and more efficient by predicting patient outcomes and reducing required sample sizes. The company provides a B2B SaaS platform that applies machine learning, deep learning, and biostatistics to create prognostic digital twins and implement TwinRCTs that integrate historical data into randomized trials. Its solution is used by pharmaceutical and biotech sponsors across therapeutic areas such as neuroscience, immunology, and metabolic disease and aligns with EMA qualification and FDA guidance. Unlearn.AI’s platform supports trial simulation, responder identification, and more precise treatment-effect estimation to de-risk trial design and accelerate development timelines.

Unlearn.AI uses AI-generated digital twins to make clinical trials faster and more efficient by predicting patient outcomes and reducing required sample sizes. The company provides a B2B SaaS platform that applies machine learning, deep learning, and biostatistics to create prognostic digital twins and implement TwinRCTs that integrate historical data into randomized trials. Its solution is used by pharmaceutical and biotech sponsors across therapeutic areas such as neuroscience, immunology, and metabolic disease and aligns with EMA qualification and FDA guidance. Unlearn.AI’s platform supports trial simulation, responder identification, and more precise treatment-effect estimation to de-risk trial design and accelerate development timelines.
Core offering: AI-generated digital twins and trial-design/analysis tools to improve clinical trials
Founded: 2017
Headcount (approx.): 66
Reported total funding: 134,850,000 USD
Key customers: Pharmaceutical and biotech sponsors (multiple therapeutic areas)
Clinical trial design and analysis for pharmaceutical and biotech development
2017
Research Services
12,000,000
Reported Series A led by 8VC with participation from DCVC, DCVC Bio, and Mubadala Capital Ventures.
50,000,000
Reported Series B with participation from Radical Ventures, 8VC, DCVC, DCVC Bio, and Mubadala.
134850000
Aggregate reported total funding amount as of this date.
“Participants include growth and specialized investors such as 8VC, Insight Partners, DCVC/DCVC Bio, Radical Ventures, Mubadala, Altimeter Capital, and Wittington Ventures”
| Company |
|---|
Our Mission and Vision
Unlearn exists to transform clinical development by making every trial smarter. We harness data, AI, and digital twins to enable faster, more robust studies that bring life-saving treatments to patients faster. This mission drives everything we do as we partner with biopharmaceutical companies to redesign how clinical trials are planned, run, and analyzed.
We are defining the future of clinical development with unmatched scientific credibility, replacing uncertainty with AI-powered precision so decisions are clearer and trials are stronger. We don’t just disrupt the pharmaceutical industry, we create lasting change.
We believe AI will define the future of medicine, and we are committed to building that future responsibly, rigorously, and in close collaboration with our partners in clinical development.
We come from a variety of backgrounds ranging from machine learning to marketing—but regardless of where we come from, Unlearners share some common traits:
Headquartered in San Francisco, Unlearn was founded in 2017 by a team of world-class machine learning scientists. We have raised venture capital from top tier investors such as Altimeter, Insight Partners, Radical Ventures, 8VC, DCVC, and DCVC Bio, and completed our $50 million Series C in January 2024.
If our purpose and culture resonate with you, we invite you to apply. Biostatistician. Biostatisticians lead Unlearn’s work to integrate state-of-the-art ML approaches into the design and analysis of clinical trials. This can be everything from utilizing PROCOVA, a methodology we developed to add power and reduce sample size in phase 2 and 3 trials, to defining and conducting Bayesian or single arm analyses or innovating solutions for custom problems. Biostatisticians at Unlearn work closely with their counterparts at customers as well as broader clinical development teams. We highly value practical experience, the determination and autonomy to own projects end-to-end, and eager collaboration with an excellent and diverse team.
Responsibilities Include
Minimum Requirements
Bonus Points For
Benefits & Perks
The following benefits and perks are for full time roles only.
Unlearn is an equal opportunity employer.
At Unlearn, we are committed to building a diverse and inclusive workplace, because inclusion and diversity are essential to achieving our mission. If you’re excited about this role, and your past experience doesn’t align perfectly with every qualification in the job description, we encourage you to apply nevertheless.